Expertise

Matthew Pakizegee

Matthew Pakizegee, PharmD

Medical Associate, Government Policy Systems

EVERSANA

Matthew Pakizegee, PharmD

Matthew supports clinical services and leads clinical content for Government Policy Systems (GPS).

He facilitates discussions with EVERSANA’s bench of payer consultants and manages government policy content including topics impacting healthcare delivery systems.

He has held a variety of roles in biopharma, some of which include landscape analyses in oncology, advisory boards for respiratory and analgesic products, and market intelligence for hypercholesterolemia products.

Matthew received a PharmD and master’s degree in healthcare decision analysis from the University of Southern California

Expertise:

Stakeholder Engagement & Promotion (Patients, Payers, Providers)

Articles by Matthew Pakizegee, PharmD

Ramifications of “Medicare for All” and Implications for Clinical Pathways

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and reimbursement. While it is certain that clinical pathways are shaping and will continue to shape health care regardless of system, what is far […]

Balancing Access

Value propositions need to justify product pricing by focusing on the burden of severe illnesses and how the products address unmet needs.

Could CMS Policies Impact Investments in CAR T-cell Therapies and Other Innovative Treatments?

Clinical pathways that include CAR T-cell therapy as an option must integrate appropriate guidance on its use and settings of care.

Will the U.S. adopt global reference pricing?

This article was written for Med Ad News Magazine There are many things that Americans get from outside our U.S. borders. Our top imports include oil, machines, and cars; our iTunes and Spotify accounts are stocked with The Beatles, U2, and Ed Sheeran; and you practically can’t go to any city in America without being […]

no-image
Pathways for Paying for Rare Disease Treatments

This article was written for Clinical Pathways Magazine Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive therapies will create financial pressure for payers’ drug budgets. Clinical pathways have demonstrated success at determining the “right treatment for the […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.